Bioadhesive for corneal repair
The present disclosure provides compositions and methods for repair and reconstruction of defects and injuries to the cornea. For example, the present disclosure provides a composition for corneal reconstruction including a methacryloyl-substituted gelatin, a visible light-activated photoinitiator, and a pharmaceutically acceptable carrier. In another example, the present disclosure provides a method for corneal reconstruction including the steps of: applying a composition and exposing the composition to visible light.
1 . A prepolymer solution for promoting general eye health, wherein the prepolymer solution comprises a methacryloyl-substituted gelatin, a visible light activated photoinitiator, and a pharmaceutically acceptable carrier, wherein the methacryloyl-substituted gelatin has a degree of methacryloyl substitution between about 30% and about 85%, wherein the prepolymer solution comprises about 5% to about 25% (w/v) of the methacryloyl-substituted gelatin, wherein the prepolymer solution further comprises at least one corneal cell or a therapeutic agent, and wherein the methacryloyl-substituted gelatin comprises methacrylamide substitution and methacrylate substitution, and a ratio of methacrylamide substitution to methacrylate substitution is between 80:20 and 99:1.
2 . The prepolymer solution of claim 1 , wherein the prepolymer solution comprises about 5% to about 15% (w/v) of the methacryloyl-substituted gelatin.
3 . The prepolymer solution of claim 1 , wherein the prepolymer solution comprises about 5% (w/v), about 10% (w/v), or about 20% (w/v) of the methacryloyl-substituted gelatin.
4 . The prepolymer solution of claim 3 , wherein the prepolymer solution comprises about 5% (w/v) of the methacryloyl-substituted gelatin.
5 . The prepolymer solution of claim 1 , wherein the visible light activated photoinitiator comprises: Eosin Y, triethanolamine, vinyl caprolactam, dl-2,3-diketo-1,7,7-trimethylnorcamphane (CQ), 1-phenyl-1,2-propadione (PPD), 2,4,6-trimethylbenzoyl-diphenylphosphine oxide (TPO), bis(2,6-dichlorobenzoyl)-(4-propylphenyl)phosphine oxide (Ir819), 4,4′-bis(dimethylamino)benzophenone, 4,4′-bis(diethylamino)benzophenone, 2-chlorothioxanthen-9-one, 4-(dimethylamino)benzophenone, phenanthrenequinone, ferrocene, diphenyl (2,4,6 trimethylbenzoyl)phosphine oxide/2-hydroxy-2-methylpropiophenone (50/50 blend), dibenzosuberenone, (benzene) tricarbonylchromium, resazurin, resorufin, benzoyltrimethylgermane, or any combination thereof.
6 . The prepolymer solution of claim 1 , comprising from 0.0125 to 0.5 mM of Eosin Y, from 0.1 to 2% w/v of triethanolamine, and from 0.05 to 1.5% w/v of vinyl caprolactam.
7 . The prepolymer solution of claim 1 , wherein the at least one corneal cell is an epithelial cell.
8 . The prepolymer solution of claim 1 , wherein the therapeutic agent is an anti-inflammatory agent.
9 . The prepolymer solution of claim 8 , wherein the anti-inflammatory agent is a corticosteroid.
10 . A method of promoting general eye health in a subject, the method comprising: applying the prepolymer solution of claim 1 to the cornea or sclera of the subject, and producing a crosslinked methacryloyl-substituted gelatin hydrogel by exposing the prepolymer solution to visible light.
11 . The method of claim 10 , wherein the at least one corneal cell is comprised within a framework of the crosslinked methacryloyl-substituted gelatin hydrogel after the crosslinked methacryloyl-substituted gelatin hydrogel is produced.
12 . The method of claim 11 , wherein the at least one corneal cell is an epithelial cell.
13 . A method of producing a crosslinked methacryloyl-substituted gelatin hydrogel, the method comprising exposing the prepolymer solution of claim 1 to visible light.
14 . The method of claim 13 , wherein the at least one corneal cell is comprised within a framework of the crosslinked methacryloyl-substituted gelatin hydrogel after the crosslinked methacryloyl-substituted gelatin hydrogel is produced.
15 . The method of claim 14 , wherein the at least one corneal cell is an epithelial cell.
16 . A crosslinked methacryloyl-substituted gelatin hydrogel produced by the method of claim 13 .
17 . The hydrogel of claim 16 , wherein the hydrogel is transparent.
18 . The hydrogel of claim 16 , wherein the at least one corneal cell is comprised within a construct of the hydrogel.